Mastrantuono Elisa, Ghibaudi Matilde, Matias Diana, Battaglia Giuseppe
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Institute for Bioengineering of Catalonia, Barcelona Institute of Science and Technology, Spain.
Mol Oncol. 2024 Dec;18(12):2966-2976. doi: 10.1002/1878-0261.13730. Epub 2024 Sep 14.
The diverse roles of the low-density lipoprotein receptor family (LDLR) have been associated with many processes critical to maintaining central nervous system (CNS) health and contributing to neurological diseases or cancer. In this review, we provide a comprehensive understanding of the LDLR's involvement in common brain tumors, specifically high-grade gliomas, emphasizing the receptors' critical role in the pathophysiology and progression of these tumors due to LDLR's high expression. We delve into LDLR's role in regulating cellular uptake and transport through the brain barrier. Additionally, we highlight LDLR's role in activating several signaling pathways related to tumor proliferation, migration, and invasion, engaging readers with an in-depth understanding of the molecular mechanisms at play. By synthesizing current research findings, this review underscores the significance of LDLR during tumorigenesis and explores its potential as a therapeutic target for high-grade gliomas. The collective insights presented here contribute to a deeper appreciation of LDLR's multifaceted roles and implications for physiological and pathological states, opening new avenues for tumor treatment.
低密度脂蛋白受体家族(LDLR)的多种作用与许多对维持中枢神经系统(CNS)健康以及导致神经疾病或癌症至关重要的过程相关。在本综述中,我们全面了解了LDLR在常见脑肿瘤,特别是高级别胶质瘤中的作用,强调了由于LDLR的高表达,这些受体在这些肿瘤的病理生理学和进展中的关键作用。我们深入探讨了LDLR在调节通过脑屏障的细胞摄取和转运中的作用。此外,我们强调了LDLR在激活与肿瘤增殖、迁移和侵袭相关的几种信号通路中的作用,使读者深入了解其中起作用的分子机制。通过综合当前的研究结果,本综述强调了LDLR在肿瘤发生过程中的重要性,并探讨了其作为高级别胶质瘤治疗靶点的潜力。这里呈现的综合见解有助于更深入地理解LDLR的多方面作用及其对生理和病理状态的影响,为肿瘤治疗开辟新途径。
Cancer Biol Ther. 2024-12-31
J Mol Neurosci. 2025-1-23
Sci Adv. 2016-3-18
Technol Cancer Res Treat. 2016-2-10
J Neurooncol. 2013-3-14
Biochim Biophys Acta Rev Cancer. 2025-4
Front Endocrinol (Lausanne). 2020